MDT

Medtronic
D

MDT

Arincen70/100B

Medtronic income statement 1986–2027

37.54B USD over the last twelve months, and 36.36B USD in fiscal year 2026.

Revenue Operating income Net income

Click a line's chart icon in the table to add it to the chart; hover over it for a quick look.

Fiscal year
TTM
31 Jul 2026
FY2026
24 Apr 2026
FY2025
25 Apr 2025
FY2024
26 Apr 2024
FY2023
28 Apr 2023
FY2022
29 Apr 2022
FY2021
30 Apr 2021
FY2020
30 Apr 2020
FY2019
26 Apr 2019
FY2018
27 Apr 2018
FY2017
28 Apr 2017
Revenue
37.54B36.36B33.54B32.36B31.23B31.69B30.12B28.91B30.56B29.95B29.71B
Revenue growth
+9.77%+8.43%+3.62%+3.64%-1.45%+5.21%+4.16%-5.38%+2.02%+0.82%+3.04%
Cost of revenue
12.51B12.72B11.63B11.22B10.72B10.15B10.48B9.42B9.16B9.07B9.29B
Gross profit
25.04B23.64B21.91B21.15B20.51B21.54B19.63B19.49B21.40B20.89B20.42B
Gross margin
66.69%65.02%65.32%65.34%65.67%67.98%65.19%67.41%70.04%69.73%68.72%
Research and development
2.92B2.87B2.73B2.74B2.70B2.75B2.49B2.33B2.33B2.26B2.19B
Selling, general and administrative
12.18B11.78B10.85B10.74B10.42B10.29B10.15B10.11B10.42B10.24B10.02B
Operating expenses
18.25B17.18B15.95B16.00B15.02B15.79B15.15B14.70B15.13B14.25B15.03B
6.79B6.47B5.96B5.14B5.49B5.75B4.48B4.79B6.27B6.64B5.38B
Operating income growth
+10.85%+8.60%+15.77%-6.22%-4.64%+28.28%-6.41%-23.56%-5.60%+23.35%+0.41%
Operating margin
18.08%17.78%17.76%15.89%17.56%18.15%14.89%16.57%20.51%22.17%18.12%
Interest income
———————————
Interest expense
725.00M715.00M729.00M719.00M636.00M553.00M925.00M1.09B1.44B1.15B1.09B
Other non-operating income
-183.00M-331.00M-327.00M-307.00M-121.00M-235.00M-589.00M-736.00M-1.07B-965.00M-781.00M
Pretax income
6.60B6.14B5.63B4.84B5.36B5.52B3.90B4.06B5.20B5.68B4.60B
Income tax
1.33B1.30B936.00M1.13B1.58B456.00M265.00M-751.00M547.00M2.58B578.00M
Effective tax rate
20.19%21.17%16.63%23.42%29.46%8.27%6.80%-18.52%10.53%45.46%12.56%
5.23B4.80B4.66B3.68B3.76B5.04B3.61B4.79B4.63B3.10B4.03B
Net income growth
+12.21%+2.96%+26.82%-2.18%-25.42%+39.74%-24.70%+3.41%+49.19%-22.94%+13.85%
Net margin
13.93%13.20%13.90%11.36%12.03%15.90%11.97%16.56%15.16%10.36%13.56%
Basic shares
1.28B1.28B1.29B1.33B1.33B1.34B1.34B1.34B1.35B1.36B1.38B
Diluted shares
1.29B1.29B1.29B1.33B1.33B1.35B1.35B1.35B1.36B1.37B1.39B
Change in diluted shares
+0.02%-0.14%-3.03%-0.20%-1.38%-0.19%+0.21%-0.47%-0.78%-1.67%-2.42%
EPS (basic)
4.093.753.632.772.833.752.683.573.442.292.92
EPS (diluted)
4.063.733.612.762.823.732.663.543.412.272.89
EPS growth
+11.85%+3.32%+30.80%-2.13%-24.40%+40.23%-24.86%+3.81%+50.22%-21.45%+16.53%
Dividends per share
2.852.842.802.762.722.522.322.162.001.841.72
Dividend growth
+1.42%+1.43%+1.45%+1.47%+7.94%+8.62%+7.41%+8.00%+8.70%+6.98%+13.16%
EBITDA
10.18B9.81B9.22B8.20B8.70B8.78B7.52B7.81B9.30B9.47B8.61B
EBITDA margin
27.11%26.97%27.49%25.35%27.85%27.70%24.98%27.01%30.43%31.60%28.99%
EBIT
7.33B6.85B6.36B5.56B6.00B6.07B4.82B5.15B6.64B6.82B5.70B

Figures in USD. Shares and EPS are adjusted for stock splits. Quarterly growth is on the same quarter a year before; TTM is the last four quarters.

Common questions about Medtronic's income statement

Source: Financial Modeling Prep

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.